© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Induction of myocardial biglycan in heart failure in rats—an extracellular matrix component targeted by AT1 receptor antagonism
aMSD Cardiovascular Research Centre, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
bInstitute for Surgical Research, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
cResearch Institute for Internal Medicine, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
dDepartment of Pharmacology, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
*Corresponding author. Institute for Surgical Research, A3.1013, Rikshospitalet University Hospital, N-0027 Oslo, Norway. Tel.: +47-23-073520; fax: +47-23-073530. Email address: havard.attramadal{at}klinmed.uio.no
Objective: Cardiac remodelling associated with congestive heart failure typically involves dilatation of the ventricular cavities, cardiomyocyte hypertrophy and alterations of extracellular matrix. Biglycan is an extracellular proteoglycan with several recently appreciated functions including cell adhesion, collagen fibril assembly, and growth factor interactions. The aims of this study were to investigate the regulation of biglycan expression and to elucidate the site(s) of synthesis of biglycan in myocardial tissue in an experimental model of heart failure (HF). Methods: Myocardial tissue samples were obtained from rats with myocardial infarction (MI) subsequent to ligation of the left coronary artery. Northern blot analysis and real-time quantitative RT-PCR were employed to investigate mRNA levels. The cellular distribution of biglycan was analysed by in situ hybridisation and immunohistochemistry. Results: Myocardial biglycan mRNA levels in non-ischemic tissue of both left and right ventricles of heart failure rats were substantially elevated as compared to sham-operated rats. Although expression levels peaked 7 days after MI (13-fold increase compared to the sham group, P<0.05), substantial elevations of biglycan mRNA were observed throughout the study period. Analysis of cellular distribution revealed that biglycan expression was confined to myocardial fibroblasts and vascular endothelial cells. In cardiac fibroblasts isolated from failing hearts, biglycan mRNA levels were markedly elevated compared with fibroblasts from sham-operated rats. In addition, in rats with ischemic heart failure treatment with the AT1 receptor antagonist losartan (12.5 mg·kg–1 b.i.d. per os, for 25 days) prevented the increase of myocardial biglycan as well as TGF-β1 mRNA. Conclusion: This report demonstrates global induction of myocardial biglycan mRNA in heart failure. Myocardial biglycan expression could be targeted by AT1 receptor antagonism, an intervention well documented to halt cardiac remodelling in heart failure. Furthermore, the study provides evidence that angiotensin II is a regulator of biglycan expression in cardiac fibroblasts.
KEYWORDS Heart failure; Remodelling; Gene expression; Extracellular matrix; Angiotensin
Time for primary review 21 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Csont and P. Ferdinandy Letter by Csont and Ferdinandy Regarding Article, "Biglycan Is Required for Adaptive Remodeling After Myocardial Infarction" Circulation, October 7, 2008; 118(15): e521 - e521. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Prante, H. Milting, A. Kassner, M. Farr, M. Ambrosius, S. Schon, D. G. Seidler, A. E. Banayosy, R. Korfer, J. Kuhn, et al. Transforming Growth Factor beta1-regulated Xylosyltransferase I Activity in Human Cardiac Fibroblasts and Its Impact for Myocardial Remodeling J. Biol. Chem., September 7, 2007; 282(36): 26441 - 26449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Colston, S. D. de la Rosa, M. Koehler, K. Gonzales, R. Mestril, G. L. Freeman, S. R. Bailey, and B. Chandrasekar Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1839 - H1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Arishiro, M. Hoshiga, N. Negoro, D. Jin, S. Takai, M. Miyazaki, T. Ishihara, and T. Hanafusa Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bouzeghrane, D. P. Reinhardt, T. L. Reudelhuber, and G. Thibault Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H982 - H991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien and D. P. Fishbein Mitral valve abnormalities in congestive heart failure: An interplay between form and function? J. Am. Coll. Cardiol., January 4, 2005; 45(1): 62 - 64. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kurdi, C. Cerutti, J. Randon, L. McGregor, and G. Bricca Macroarray analysis in the hypertrophic left ventricle of renin-dependent hypertensive rats: identification of target genes for renin Journal of Renin-Angiotensin-Aldosterone System, June 1, 2004; 5(2): 72 - 78. [Abstract] [PDF]
|
|